Medical Newswire

Medical Newswire!

Medicine, Healthcare, Medical Research, Hospitals, Management
Press release distribution service
Home | Medical-Newswire.Com:

Yasmin Settlements Climb to $142 Million

(EMAILWIRE.COM, May 18, 2012 ) New York, NY – Yasmin settlements have climbed to $142 million, averaging $218,000 per case, according to a number of news sources. Bayer has reportedly resolved 651 lawsuits alleging that its Yasmin and Yaz birth control pills caused sometimes-fatal blood clots in women, with one financial analyst reportedly estimating that Bayer may have to pay out more than $2.65 billion to resolve all cases surrounding these oral contraceptives. If you or a loved one suffered a blood clot while taking Yaz or Yasmin, you may still be able to file a claim against the manufacturer to seek compensation for medical expenses and other losses. To learn more about the Yasmin settlements and to have your claim evaluated at no cost to you, please visit http://www.classaction.org/yaz-yasmin.html today.

The news of the Yasmin settlements came shortly after the FDA ordered a stronger blood clot warning on Yaz and Yasmin labels. The new labels will include information that some studies have found up to a threefold increase in the risk of blood clots with pills containing drospirenone, a hormone found in Yaz, Yasmin and other newer, fourth-generation birth control pills. The agency’s own study found that 10 in 10,000 women taking oral contraceptives containing this synthetic hormone would get a blood clot per year, compared to approximately six in 10,000 women using older birth control pills. This announcement of the label update was made after an advisory committee of outside experts to the agency voted for pills containing drospirenone to undergo a label revision to more clearly outline their risks and benefits.

Reportedly, Bayer is facing 11,900 lawsuits over its Yaz and Yasmin oral contraceptives. Bayer has agreed to settle the first group of lawsuits for venous clot injuries – deep vein thrombosis (DVT) or pulmonary embolism (PE) - while other suits are still in progress. If you suffered a venous clot injury while taking Yaz or Yasmin, it’s not too late to make a claim. For a free evaluation of your blood clot claim, visit ClassAction.org today.

About Class Action.org

Class Action.org is dedicated to protecting consumers and investors in class actions and complex litigation throughout the United States. Class Action.org keeps consumers informed about product alerts, recalls, and emerging litigation and helps them take action against the manufacturers of defective products, drugs, and medical devices. Information about consumer fraud issues and environmental hazards is also available on the site. Visit http://www.classaction.org today for a no cost, no obligation case evaluation and information about your consumer rights.

ClassAction.org
Hannah Armstrong
800-449-1970
pressrelease@lawyercentral.com

Source: EmailWire.com


Medical Resources
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Healthcare resource center today to browse our selection of 600+ complimentary Healthcare magazines, white papers, webinars, podcasts, and more. Get popular titles including:

Eyecare Business
Medical Laboratory Observer
FierceHealthcare

No credit cards, coupons, or promo codes required. Try it today!

Medical Sponsors

Health News
Health News Headlines - Yahoo News
Health News Headlines - Yahoo News
Get the latest health news headlines from Yahoo News. Find breaking health news, including analysis and opinion on top health stories.


Health care site flagged in Heartbleed review
18 Apr 2014 at 10:18pm

WASHINGTON (AP) ? People who have accounts on the enrollment website for President Barack Obama's signature health care law are being told to change their passwords following an administration-wide review of the government's vulnerability to the confounding Heartbleed Internet security flaw.


Study: Half of jailed NYC youths have brain injury
18 Apr 2014 at 2:29pm
NEW YORK (AP) ? About half of all 16- to 18-year-olds coming into New York City's jails say they had a traumatic brain injury before being incarcerated, most caused by assaults, according to a new study that's the latest in a growing body of research documenting head trauma among young offenders.

Second wave of milder flu hitting Northeast
18 Apr 2014 at 2:16pm
NEW YORK (AP) ? A second, milder wave of flu is hitting the Northeast.

APNewsBreak: Medicaid paid $12M for Illinois dead
18 Apr 2014 at 4:42pm
CHICAGO (AP) ? The Illinois Medicaid program paid an estimated $12 million for medical services for people listed as deceased in other state records, according to an internal state government memo.

Watch: Scientists Engineer Lab-Grown Vaginas
18 Apr 2014 at 3:03pm
Four women with a genetic condition took part in a ground-breaking study.

Yoga may help women ease PTSD symptoms
18 Apr 2014 at 2:36pm
By Shereen Jegtvig NEW YORK (Reuters Health) - Women enrolled in a small study reported a reduction in symptoms of posttraumatic stress disorder (PTSD) after a series of yoga classes. However, women in a comparison group that didn't take the classes also reported a similar decline in symptoms, researchers found. "The yoga group did well - they improved in their PTSD symptoms - and our control group actually did well, which we didn't expect," Karen Mitchell told Reuters Health. Mitchell, from the National Center for PTSD at the VA Boston Healthcare System, led the new study.


Supreme Court denies Teva stay in Copaxone patent fight
18 Apr 2014 at 1:49pm

By Lawrence Hurley WASHINGTON (Reuters) - U.S. Supreme Court Chief Justice John Roberts on Friday denied a request by Teva Pharmaceutical Industries Ltd to stay a lower-court ruling in a patent case that favored the developers of generic versions of Teva's top-selling multiple sclerosis drug. The decision could help pave the way for generic competitors of Teva's Copaxone drug to go on the market as soon as next month. Teva had sought to prevent the lower-court ruling from going into effect while the Supreme Court considers its appeal in the patent fight. At issue is a July 2013 ruling by the U.S. Court of Appeals for the Federal Circuit in favor of two teams developing cheaper generic forms of Copaxone: one comprising Novartis AG's Sandoz Inc and Momenta Pharmaceuticals Inc, and the other comprising Mylan Inc and Natco Pharma Ltd. In his decision on Friday, Roberts, in a brief opinion, wrote that he was not convinced Teva had shown the "likelihood of irreparable harm" if the application was denied, because if Teva wins the Supreme Court case it can seek damages from the generic companies for past infringement on its patents.


AbbVie urges U.S. court to avoid gay rights issue in HIV drug case
18 Apr 2014 at 12:57pm
An Abbott Laboratories spinoff urged a federal appeals court to revisit a ruling in a case against GlaxoSmithKline Plc, but without disturbing landmark constitutional protections for gays and lesbians. In a brief filed with the 9th U.S. Circuit Court of Appeals in San Francisco on Thursday, AbbVie Inc said the full court should review an initial three-judge decision that found a gay man was improperly excluded from jury service due to his sexual orientation. The court in reaching that conclusion in January ordered a new trial for GlaxoSmithKline Plc against AbbVie, which contended Thursday that the 9th Circuit's ruling needed review due to its potential to affect "thousands of jury trials." But AbbVie said it is not asking for the court to reconsider a holding that heightened the constitutional protections judges in several Western states must now apply when evaluating laws that curtail gay rights.


Top Hollande aide quits in conflict of interest row
18 Apr 2014 at 12:43pm

By Julien Ponthus and Nicholas Vinocur CLERMONT-FERRAND, France (Reuters) - A senior adviser to French President Francois Hollande quit on Friday over accusations of past conflict of interest linked to his work for pharmaceutical firms, adding to pressure on the unpopular Socialist leader weeks before European elections. Aquilino Morelle, Hollande's chief communications adviser, speechwriter and a main political strategist, has denied investigative website Mediapart's report that he had failed to obtain clearance for lobbying work when he was an employee of the public health inspectorate. The furore deals another blow to Hollande after heavy losses for his party in town hall elections at the end of March. Hollande, speaking during a visit to Clermont Ferrand in central France, said his aide had "taken the only option open to him".



Clock ticking for states to adopt health exchanges
18 Apr 2014 at 12:12pm

CHICAGO (AP) ? For the more than 30 states that defaulted to the federal government under President Barack Obama's health care law, time may be running out to decide whether to create their own state-run insurance exchanges.


Watch: Baby Can't Open Mouth in Medical Mystery
18 Apr 2014 at 12:09pm
Video shows doctors assessing Wyatt Scott's ability to swallow.

Baby Can?t Open Mouth in Medical Mystery
18 Apr 2014 at 12:08pm
The Scott family started a website to find out what's wrong with baby Wyatt.


Exclusive: Biogen prices hemophilia drug on par with older therapies
18 Apr 2014 at 12:04pm

Biogen Idec Inc is pricing its newly approved long-acting hemophilia drug, Alprolix, to cost U.S. patients, and insurers, about the same per year as older, less convenient therapies whose price can reach about $300,000 annually. The move could pressure rivals such as Pfizer Inc to lower prices for existing hemophilia treatments, which provide patients with life-saving infusions of a blood clotting agent, according to doctors and industry analysts. Biogen last month won U.S. and Canadian approval for Alprolix to treat hemophilia B, the more rare form of the condition that affects about 4,000 people in the United States and about 25,000 worldwide. "We think we have priced (Alprolix) to create parity with existing therapies on an annual cost of therapy basis," Tony Kingsley, Biogen's head of global commercial operations, told Reuters in a telephone interview.


Lack of insurance tied to more emergency surgery: study
18 Apr 2014 at 12:01pm
By Andrew M. Seaman NEW YORK (Reuters Health) - The type of insurance people have is tied to their risk of needing emergency aorta surgery, according to a new study. Compared to people with private insurance, people without insurance were more likely to need emergency surgery on their aorta, the largest artery that supplies blood to every part of the body. Hughes is the study's senior author from Duke University Medical Center in Durham, North Carolina.

NJ Mumps Victims Were Vaccinated, Officials Say
18 Apr 2014 at 11:11am
At least eight students have contacted the virus.

Pharmanewswire.com is part of GropWeb Network, online properties of GroupWeb Media LLC. Copyright © GroupWeb Media LLC. All Rights Reserved.

For unlimited press release distribution for $99 per month, call (281) 645-4086 or start posting your press releases online at EmailWire.com. CityRegions.Com is part of GropWeb Network, online properties of GroupWeb Media LLC. Copyright © 2012 GroupWeb Media LLC. All Rights Reserved.


GroupWeb Media Network
AfricaNewswire.Net | AppleNews247.Com | AsiaNewsWire.Net | Aviation-NewsWire | Energy Industry | EstateNewsWire | Entertainment-NewsWire.com | Food Beverage News | Glamour NewsWire | Health NewsWire | Hosting NewsWire | i-Auto NewsWire | i-Business News | EuropeNewsWire.Net | iCameroon.com | i-Canada-News.Com | i-SoftwareNews.com | iT-NewsWire.Com
| InvestorsNewsDesk.Com | i-TravelNewsWire.Com | LegalLaw247.com | Medical-NewsWire.com | MiningNewsWire.net | MoneyNewsWire.Net | Movie-Stars-News.Com | PayDayNews247.Com | PharmaNewsWire.Com | Publishing-NewsWire.Com | Shopping-NewsWire.com | Telecom-NewsWire.Net | Transportation-News.Com | USGovernment-News.Com | WebPosters.Net | Wireless-NewsWire.Com |
Medical-Newswire.com - Medicl Newswire and Press Release service of GroupWeb Media LLC